0000899243-18-007359.txt : 20180314 0000899243-18-007359.hdr.sgml : 20180314 20180314132136 ACCESSION NUMBER: 0000899243-18-007359 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180306 FILED AS OF DATE: 20180314 DATE AS OF CHANGE: 20180314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Barclay Alec CENTRAL INDEX KEY: 0001734339 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36571 FILM NUMBER: 18689019 MAIL ADDRESS: STREET 1: 101 HARTWELL AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: T2 Biosystems, Inc. CENTRAL INDEX KEY: 0001492674 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204827488 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-457-1200 MAIL ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-03-06 0 0001492674 T2 Biosystems, Inc. TTOO 0001734339 Barclay Alec 101 HARTWELL AVENUE LEXINGTON MA 02421 0 1 0 0 SVP, Operations Common Stock 890 D Stock Option 9.32 2026-04-25 Common Stock 15000 D Stock Option 6.79 2026-09-12 Common Stock 10000 D Stock Option 5.19 2027-01-05 Common Stock 15000 D Restricted Stock Unit Common Stock 20000 D Stock Option 5.08 2028-03-01 Common Stock 90000 D This Stock Option was granted on April 25, 2016 and vesting commenced on the grant date. Options to purchase 25% of the total underlying shares vest on the first anniversary of the vesting commencement date and options to purchase the remaining shares vest in 36 equal monthly installments thereafter. This Stock Option was granted on September 12, 2016 and vesting commenced on the grant date. Options to purchase the underlying shares vest in 48 equal monthly installments beginning on the grant date. This Stock Option was granted on January 5, 2017 and vesting commenced on the grant date. Options to purchase the underlying shares vest in 48 equal monthly installments beginning on the grant date. The restricted stock units vest in two annual installments beginning on September 11, 2017. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. This Stock Option was granted on March 1, 2018 and vesting commenced on the grant date. Options to purchase the underlying shares vest in 48 equal monthly installments beginning on the grant date. Exhibit List: Exhibit 24 - Power of Attorney /s/ Michael Gibbs 2018-03-14 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                  T2 BIOSYSTEMS, INC.

                                   POWER OF ATTORNEY

        Know all by these presents, that the undersigned hereby constitutes and
appoints the (i) General Counsel of T2 Biosystems, Inc. (the "Company"), who is
currently Michael Gibbs, (ii) Chief Financial Officer of the Company, who is
currently John Sprague, and (iii) Controller of the Company, who is currently
Scott Allen, and their respective successors, the undersigned's true and lawful
attorneys-in-fact to:

        (1)        execute for and on behalf of the undersigned, in the
undersigned's capacity as a beneficial owner of the Company, Forms 3, 4, and 5
in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;

        (2)        do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute any such
Form 3, 4, or 5 and timely file such form with the United States Securities and
Exchange Commission and any stock exchange or similar authority; and

        (3)        take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of any such attorney-in-fact, may be of
benefit to, in the best interest of, or legally required by, the undersigned, it
being understood that the documents executed by any such attorney-in-fact on
behalf of the undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such attorney-in-fact may
approve in such attorney-in-fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that neither of
the foregoing attorneys-in- fact, in serving in such capacity at the request of
the undersigned, is assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to each
of the foregoing attorneys- in-fact.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 12th day of March, 2018.


                                        /s/ Alec Barclay
                                        ----------------------------------------
                                        Name: Alec Barclay